Oxidative Stress Appears in Brain Cells Before Amyloid Plaques

Research into the causes of Alzheimer's Disease shows that amyloid plaques develop while the illness is taking over the brain but still not clinically evident. Accordingly, the most common scientific belief holds that those plaques contribute to or cause the oxidative damage and inflammation that occur and, ultimately, destroy brain cells.

Now, a mouse-model study at the University of Pennsylvania School of Medicine has demonstrated that oxidative damage precedes the plaques -- a reversal of existing theory that opens new paths of inquiry in combatting an illness that afflicts one out of every 10 persons over the age of 65.

"Alzheimer's Disease is a very complex disease that does not appear to have a single cause, but our research indicates that oxidative stress is probably a primary event in the course of the illness," said Domenico Pratico, MD, of the Department of Pharmacology in Penn's School of Medicine and a member of Penn's Center for Experimental Therapeutics. He is corresponding author of the study, which will be published Friday in the June 15 issue of The Journal of Neuroscience.

The primary target of Alzheimer's Disease (AD) is the hippocampus, followed by the frontal and temporal lobes of the brain, all of which can lose between 30 and 40 percent of their neurons as the disease progresses.
Most scientists investigating the illness base their work on one of two main theories.

The first holds that as amyloid plaques develop, they cause an inflammation in microglia cells that backfires, stimulating the production of cytokines that attack and damage neurons.

The second theory is based on the action of free radicals. About 95 percent of the brain is made up of fatty lipids that, when attacked by free radicals, undergo peroxidation (oxidative damage.) That leads, in turn, to cell malfunction and eventual cell death. It is known that amyloid beta protein can produce free radicals on its own, as well as stimulate other cells to do the same. Many scientists believe that a build-up of amyloid plaques causes a parallel increase in free radicals, which eventually reach the point where they overwhelm the brain's power to destroy them -- resulting in what is called oxidative stress.

At the core of both theories is the belief that amyloid plaques constitute an initiating factor in the onset of Alzheimer's Disease. Pratico and his colleagues decided to establish whether that is true. They discovered that free radicals show up even earlier on the scene.
The scientists studied mice that had been engineered to produce amyloid-beta plaque at a rapid rate.

The Penn researchers studied the brains of the engineered animals and a control group at six developmental milestones: four weeks, four months, eight months, 12 months, 15 months, and 18 months.

"At seven months, there is 25 percent more oxidative damage in the AD mice than is present in normal mice, and this differential keeps increasing until it is 100 percent higher at 10 or 11 months," Pratico said. "At 12 months, oxidative damage is 200 percent higher" than in the normal mice.

In the engineered mice, the plaques were still undetectable at eight months.

"This opens a lot of interesting hypotheses for therapeutics," Pratico said. "If you reduce oxidative stress in these animals very early, when they are very young, can you prevent the formation of amyloid? And by how much? We know Vitamin E, which is an anti-oxidant, can temporarily slow the progression of AD for some patients. What we don't yet know is what will happen if we suppress, reduce or delay oxidative stress over the long run."

Others who collaborated in the study were Kunihiro Uryu, PhD, John Q, Trojanowski, MD, PhD, and Virginia M.-Y Lee, PhD, of Penn's Department of Pathology and Laboratory Medicine. Trojanowski and Lee are codirectors of the Center for Neurodegenerative Disease Research, and Uryu is a member of the center's staff.

The research was funded by the American Heart Association, the National Institute on Aging, the National Institutes of Health, and the Oxford Foundation.




Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.

Share This Page: